Residency · Dallas, TX
Sponsored by University of Texas Southwestern Medical Center
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
The Lancet. Neurology · 2021 · 399 citations · Susan Iannaccone
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Nature medicine · 2022 · 263 citations · Susan Iannaccone
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
Nature medicine · 2022 · 236 citations · Susan Iannaccone
Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.
The New England journal of medicine · 2022 · 184 citations · Lina Chalak
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
JAMA neurology · 2024 · 94 citations · Benjamin Greenberg
Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
Annals of neurology · 2024 · 88 citations ·
Cerebral Oximetry Monitoring in Extremely Preterm Infants.
The New England journal of medicine · 2023 · 86 citations · Lina Chalak
Whole-Body Hypothermia for Neonatal Encephalopathy in Preterm Infants 33 to 35 Weeks' Gestation: A Randomized Clinical Trial.
JAMA pediatrics · 2025 · 44 citations · Lina Chalak